Tags

Type your tag names separated by a space and hit enter

Pathogenesis, clinical findings and management of acute and chronic gout.
Minerva Med. 2006 Dec; 97(6):495-509.MM

Abstract

Gout is a chronic metabolic disease caused by a disorder of the purine metabolism leading to hyperuricaemia. It is determined by the deposition of monosodium urate crystals in joints and other tissues which causes an acute inflammatory response and can induce a permanent tissue damage which defines the urate chronic joint disease which is characterised by the appearance of ulceration of the joint cartilage, marginal osteophytosis, geodic and erosive lesions and chronic inflammation of synovial membrane. Gout and hyperuricaemia usually occur after the age of 30 years and more frequently in men. Hyperuricaemia is the result of an increased production of uric acid or its hypoexcretion by the kidneys, or both. In the pathogenesis of gout and hyperuricaemia are involved genetic and environmental factors; further, different pathologic condition such as glycogenosis, renal insufficiency, use of some drugs, are associated with gout. Treatment of acute gout includes colchicine, nonsteroidal anti-inflammatory drugs and glucocorticoids, whereas in the intercritical periods colchicine is effective for preventive purposes. Urate-lowering therapy with xanthine-oxidase inhibitors or uricosuric agents is indicate only in patients with more than two gout crisis per year, tophaceous deposits, uric acid nephrolithiasis, and interstitial renal disease, as asymptomatic hyperuricaemia does not requires any treatment but can be controlled with preventive dietetic measures and changes in lifestyle.

Authors+Show Affiliations

Unit of Rheumatology, University of Foggia, Hospital Colonello D'Avanzo, Foggia, Italy. ada_corrado@libero.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17213786

Citation

Corrado, A, et al. "Pathogenesis, Clinical Findings and Management of Acute and Chronic Gout." Minerva Medica, vol. 97, no. 6, 2006, pp. 495-509.
Corrado A, D'Onofrio F, Santoro N, et al. Pathogenesis, clinical findings and management of acute and chronic gout. Minerva Med. 2006;97(6):495-509.
Corrado, A., D'Onofrio, F., Santoro, N., Melillo, N., & Cantatore, F. P. (2006). Pathogenesis, clinical findings and management of acute and chronic gout. Minerva Medica, 97(6), 495-509.
Corrado A, et al. Pathogenesis, Clinical Findings and Management of Acute and Chronic Gout. Minerva Med. 2006;97(6):495-509. PubMed PMID: 17213786.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pathogenesis, clinical findings and management of acute and chronic gout. AU - Corrado,A, AU - D'Onofrio,F, AU - Santoro,N, AU - Melillo,N, AU - Cantatore,F P, PY - 2007/1/11/pubmed PY - 2007/3/14/medline PY - 2007/1/11/entrez SP - 495 EP - 509 JF - Minerva medica JO - Minerva Med VL - 97 IS - 6 N2 - Gout is a chronic metabolic disease caused by a disorder of the purine metabolism leading to hyperuricaemia. It is determined by the deposition of monosodium urate crystals in joints and other tissues which causes an acute inflammatory response and can induce a permanent tissue damage which defines the urate chronic joint disease which is characterised by the appearance of ulceration of the joint cartilage, marginal osteophytosis, geodic and erosive lesions and chronic inflammation of synovial membrane. Gout and hyperuricaemia usually occur after the age of 30 years and more frequently in men. Hyperuricaemia is the result of an increased production of uric acid or its hypoexcretion by the kidneys, or both. In the pathogenesis of gout and hyperuricaemia are involved genetic and environmental factors; further, different pathologic condition such as glycogenosis, renal insufficiency, use of some drugs, are associated with gout. Treatment of acute gout includes colchicine, nonsteroidal anti-inflammatory drugs and glucocorticoids, whereas in the intercritical periods colchicine is effective for preventive purposes. Urate-lowering therapy with xanthine-oxidase inhibitors or uricosuric agents is indicate only in patients with more than two gout crisis per year, tophaceous deposits, uric acid nephrolithiasis, and interstitial renal disease, as asymptomatic hyperuricaemia does not requires any treatment but can be controlled with preventive dietetic measures and changes in lifestyle. SN - 0026-4806 UR - https://www.unboundmedicine.com/medline/citation/17213786/Pathogenesis_clinical_findings_and_management_of_acute_and_chronic_gout_ L2 - https://medlineplus.gov/gout.html DB - PRIME DP - Unbound Medicine ER -